Literature DB >> 24751168

Impact of age on the association between CKD and the risk of future coronary events.

Marcello Tonelli1, Paul Muntner2, Anita Lloyd3, Braden Manns4, Scott Klarenbach5, Neesh Pannu3, Matthew James4, Brenda Hemmelgarn4.   

Abstract

BACKGROUND: Elucidation of the relationship between age, kidney function, and absolute coronary risk would facilitate efforts to promote chronic kidney disease (CKD) as a high-risk state for future vascular events and justify current recommendations for statin treatment in CKD. STUDY
DESIGN: Population-based study. SETTING &amp; PARTICIPANTS: 1,268,538 people with data for estimated glomerular filtration rate and albuminuria who were treated in a single Canadian province. PREDICTORS: CKD risk groups (G1, G2, G3a, G3b, and G4 had estimated glomerular filtration rate ≥90, 60-89.9, 45-59.9, 30-44.9, and 15-29.9 mL/min/1.73 m2, respectively; A1, A2, and A3 had albuminuria with albumin-creatinine ratio [ACR]<30 mg/g or dipstick urinalysis negative, ACR of 30-300 mg/g or dipstick trace or 1+, and ACR >300 mg/g or dipstick ≥ 2+, respectively) and age (<40, 40-49, ≥50 years). OUTCOMES: Rates of coronary death or nonfatal myocardial infarction (expressed per 1,000 person-years), stratified by age, sex, and CKD stage. MEASUREMENTS: The first available serum creatinine value and the corresponding date were set as the index serum creatinine value and index date, respectively. ACR or dipstick urinalysis data were obtained from the periods defined by 6 months before and after the index creatinine value.
RESULTS: Absolute rates of coronary death or nonfatal myocardial infarction were consistently greater than 10 per 1,000 person-years for people with CKD and 50 years or older, regardless of CKD stage. However, absolute rates of the composite outcome were consistently less than 10 per 1,000 person-years for those younger than 50 years. LIMITATIONS: Single Canadian province, median follow-up only 4.0 years.
CONCLUSIONS: People with CKD who are 50 years or older should be considered at the highest risk of coronary events. In contrast, consideration of other risk factors will be required when assessing future risk among people with CKD who are younger than 50 years.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary heart disease (CHD); chronic kidney disease (CKD); coronary risk; epidemiological study; future coronary events; nonfatal myocardial infarction (MI); statin treatment

Mesh:

Substances:

Year:  2014        PMID: 24751168     DOI: 10.1053/j.ajkd.2014.03.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

1.  [Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure].

Authors:  L Lauder; S Ewen; I E Emrich; M Böhm; F Mahfoud
Journal:  Herz       Date:  2019-11       Impact factor: 1.443

2.  Patient and physician perspectives on shared decision-making for coronary procedures in people with chronic kidney disease: a patient-oriented qualitative study.

Authors:  Juli Finlay; Todd Wilson; Pantea Amin Javaheri; Winnie Pearson; Carol Connolly; Meghan J Elliott; Michelle M Graham; Colleen M Norris; Stephen B Wilton; Matthew T James
Journal:  CMAJ Open       Date:  2020-12-10

3.  Graft Function, Albuminuria, and the Risk of Hemorrhage and Thrombosis After Kidney Transplantation.

Authors:  Rachel Jeong; Robert R Quinn; Pietro Ravani; Feng Ye; Manish M Sood; David Massicotte-Azarniouch; Marcello Tonelli; Brenda R Hemmelgarn; Ngan N Lam
Journal:  Can J Kidney Health Dis       Date:  2020-10-08

4.  Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation.

Authors:  Ngan N Lam; Scott Klarenbach; Robert R Quinn; Brenda Hemmelgarn; Marcello Tonelli; Feng Ye; Pietro Ravani; Aminu K Bello; Daniel C Brennan; Krista L Lentine
Journal:  Transplant Direct       Date:  2018-09-06

5.  Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.

Authors:  Hugh Gallagher; Jennifer Dumbleton; Tom Maishman; Amy Whitehead; Michael V Moore; Ahmet Fuat; David Fitzmaurice; Robert A Henderson; Joanne Lord; Kathryn E Griffith; Paul Stevens; Maarten W Taal; Diane Stevenson; Simon D Fraser; Mark Lown; Christopher J Hawkey; Paul J Roderick
Journal:  Trials       Date:  2022-04-21       Impact factor: 2.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.